The U.S. Food and Drug Administration (FDA) has given final approval to Banner Life Sciences’ Bafiertam (monomethyl fumarate), a bioequivalent alternative to Biogen’s Tecfidera (dimethyl fumarate) to treat people with relapsing…
Scientists have identified a link between systemic inflammation and fat (lipid) metabolism that may underlie the increased risk of cardiovascular disease in people with multiple sclerosis (MS). The study with that finding, “Lipoprotein profiling in early…
People in Japan with lesions in the cerebral cortex due to multiple sclerosis (MS) were found to have greater cognitive problems, or difficulties thinking, than those without lesions in this area of mostly gray matter that surrounds the brain, a study reports. Lesions confined to the…
Immune cells from patients with relapsing-remitting multiple sclerosis (RRMS) respond differently to Tecfidera (dimethyl fumarate) based on age, gender, and serum blood glucose levels, a study found. The results suggest these patient-specific factors can modulate the response of immune cells, and should be…
Treating people with relapsing-remitting multiple sclerosis (RRMS) for one year with the immune-modulating therapy Gilenya (fingolimod) reduced the numbers of antibody-producing B-cells and of T helper cells, a study finds. While the…
People with multiple sclerosis (MS) who self-identify black African or Latin American have a higher number of disease-associated antibody-secreting cells in their blood compared to those who identify as Caucasian, a U.S. study reports. This difference may account for disparities related to ethnicity in MS…
A risk of multiple sclerosis rises in people with specific variations in a protein, called the vitamin D receptor, that affects how this vitamin works and is metabolized in the body, a study drawn from a meta-analysis reports. Its researchers suggest these variations, or changes…
A DNA analysis to identify changes in the gut microbiome in people newly diagnosed with multiple sclerosis — who have yet to begin using disease-modifying therapies — showed that all, regardless of ethnic background, have an abundance of the bacteria group Clostridia compared to people…
Stopping the migration of immune B-cells through the blood-brain barrier by blocking ALCAM, a molecule linked to the progression of multiple sclerosis (MS), lessened disease severity in an MS mouse model, a new study shows. Details of the discovery were reported…
Exposure to UV-B light prevented multiple sclerosis (MS)-like symptoms in a mouse model regardless of the presence of vitamin D or the vitamin D receptor, a new study discovered. The study, “UV light suppression of EAE (a mouse…
Depleting microbes in the gut of mice led to an altered fear response, changes in gene expression in brain immune cells and changes in brain chemistry — returning to a more normal state after their gut microbes were restored, but only if done early in life, a study…
Multiple sclerosis (MS) experts discuss disease causes and current treatment options in a new video series released by the multimedia and peer-reviewed science journal, The American Journal of Managed Care (AJMC). The free and online video series is part…
Relationships between multiple sclerosis patients and their intimate partners were enhanced when the couple worked together to make lifestyle changes, and to develop skills to improve communication, a study shows.Â
The development of new medicines to treat myelin-related neurological diseases, such as multiple sclerosis (MS), has been given a boost by a €2.9 million (about $3.2 million) research grant awarded to the Belgian biotech company Rewind Therapeutics by…
No excessive relapse risk appears to exist for people with multiple sclerosis who undergo surgery that requires anesthesia, researchers report, challenging long-held assumptions associated with MS and surgery. Their single-site study, “Multiple sclerosis relapse risk in the postoperative period: Effects of…
Routine screening through magnetic resonance imaging (MRI) of people with multiple sclerosis (MS) can predict long-term disease progression — leading to more certainty and informing better treatment choices, a 15-year study reported. The study, titled “Early imaging predictors of long-term…
A first healthy volunteer has enrolled in a randomized, double-blind Phase 1 study to compare the gastrointestinal (GI) tolerability and safety of oral Tecfidera to Bafiertam, an oral bioequivalent in treating relapsing forms of multiple sclerosis (MS), Banner Life Sciences…
People whose advanced progressive multiple sclerosis (MS) limits their mobility can strengthen their lower limbs and improve life quality by engaging in regular standing exercises in their homes, a U.K. study into physiotherapy programs for this patient group reports. The study, “Assessment…
Get regular updates to your inbox.
